Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -35.16 Million USD | 49.46% |
| 2023 | -19.95 Million USD | -4.74% |
| 2022 | -19.05 Million USD | 25.2% |
| 2021 | -25.47 Million USD | -513.36% |
| 2020 | 6.16 Million USD | 273.07% |
| 2019 | 1.65 Million USD | -86.04% |
| 2018 | 11.83 Million USD | 220.02% |
| 2017 | -9.85 Million USD | -181.53% |
| 2016 | 12.09 Million USD | 34652.79% |
| 2015 | -35 Thousand USD | -106.41% |
| 2014 | 546 Thousand USD | -92.74% |
| 2013 | 7.51 Million USD | -80.36% |
| 2012 | 38.27 Million USD | -68.34% |
| 2011 | 120.92 Million USD | 2198468.82% |
| 2010 | 5500.00 USD | -99.38% |
| 2009 | 890.7 Thousand USD | -2.1% |
| 2008 | 909.8 Thousand USD | -45.82% |
| 2007 | 1.67 Million USD | -40.49% |
| 2006 | 2.82 Million USD | 461.11% |
| 2005 | 502.88 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -9.58 Million USD | -19.73% |
| 2024 Q4 | -9.58 Million USD | 0.0% |
| 2024 FY | -9.98 Million USD | 49.97% |
| 2024 Q1 | -8 Million USD | -21.82% |
| 2024 Q2 | -8 Million USD | 0.0% |
| 2023 Q3 | -4.17 Million USD | 32.82% |
| 2023 Q1 | -3.11 Million USD | 63.12% |
| 2023 Q4 | -6.56 Million USD | -57.49% |
| 2023 FY | -19.95 Million USD | -4.74% |
| 2023 Q2 | -6.2 Million USD | -99.08% |
| 2022 Q3 | -3.76 Million USD | 9.95% |
| 2022 Q4 | -8.45 Million USD | -124.64% |
| 2022 FY | -19.05 Million USD | 25.2% |
| 2022 Q1 | -3.82 Million USD | 21.05% |
| 2022 Q2 | -4.18 Million USD | -9.41% |
| 2021 Q2 | -4.57 Million USD | 83.11% |
| 2021 Q1 | -27.07 Million USD | -10.85% |
| 2021 Q4 | -4.83 Million USD | 8.95% |
| 2021 FY | -25.47 Million USD | -513.36% |
| 2021 Q3 | -5.31 Million USD | -16.19% |
| 2020 Q4 | -24.42 Million USD | -146.49% |
| 2020 FY | 6.16 Million USD | 273.07% |
| 2020 Q3 | -9.91 Million USD | 42.82% |
| 2020 Q2 | -17.33 Million USD | -222.27% |
| 2020 Q1 | 14.17 Million USD | 123.51% |
| 2019 Q3 | -1.94 Million USD | 44.94% |
| 2019 Q2 | -3.53 Million USD | -148.24% |
| 2019 Q1 | 7.32 Million USD | 1838.72% |
| 2019 FY | 1.65 Million USD | -86.04% |
| 2019 Q4 | -60.29 Million USD | -3001.65% |
| 2018 Q1 | 297 Thousand USD | 150.86% |
| 2018 FY | 11.83 Million USD | 220.02% |
| 2018 Q3 | -718 Thousand USD | -105.75% |
| 2018 Q2 | 12.48 Million USD | 4102.69% |
| 2018 Q4 | -421 Thousand USD | 41.36% |
| 2017 Q3 | -2.92 Million USD | 9.6% |
| 2017 Q4 | -584 Thousand USD | 80.06% |
| 2017 FY | -9.85 Million USD | -181.53% |
| 2017 Q2 | -3.24 Million USD | -11.72% |
| 2017 Q1 | -2.9 Million USD | -115.14% |
| 2016 Q2 | -4.1 Million USD | -413.28% |
| 2016 Q3 | -3.57 Million USD | 12.79% |
| 2016 FY | 12.09 Million USD | 34652.79% |
| 2016 Q1 | 1.31 Million USD | 15.22% |
| 2016 Q4 | 19.15 Million USD | 635.29% |
| 2015 Q3 | -1.06 Million USD | 9.28% |
| 2015 Q4 | 1.13 Million USD | 206.76% |
| 2015 Q2 | -1.17 Million USD | -209.93% |
| 2015 Q1 | 1.06 Million USD | 126.56% |
| 2015 FY | -35 Thousand USD | -106.41% |
| 2014 Q2 | -286.18 Thousand USD | -104.58% |
| 2014 Q4 | -4.02 Million USD | -1.27% |
| 2014 FY | 546 Thousand USD | -92.74% |
| 2014 Q1 | 6.24 Million USD | 131.68% |
| 2014 Q3 | -3.96 Million USD | -1287.18% |
| 2013 Q4 | 2.69 Million USD | -12.05% |
| 2013 FY | 7.51 Million USD | -80.36% |
| 2013 Q3 | 3.06 Million USD | 0.0% |
| 2012 FY | 38.27 Million USD | -68.34% |
| 2011 FY | 120.92 Million USD | 2198468.82% |
| 2010 FY | 5500.00 USD | -99.38% |
| 2009 FY | 890.7 Thousand USD | -2.1% |
| 2008 FY | 909.8 Thousand USD | -45.82% |
| 2007 FY | 1.67 Million USD | -40.49% |
| 2006 FY | 2.82 Million USD | 461.11% |
| 2005 FY | 502.88 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1441802.419% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 400.427% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -10906.958% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 129.526% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | -36.321% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -72773.454% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -28203.998% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 334.469% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1133820.181% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 459.077% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 53605.355% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -102880.966% |
| Marizyme, Inc. | 457.7 Thousand USD | 7783.602% |
| Genus plc | 178.7 Million USD | 119.68% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 115.978% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 56616.569% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 8674.11% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -319609.091% |
| ContraFect Corporation | -154 Thousand USD | -22736.364% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -70236.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 45914.932% |
| IMV Inc. | -962.29 Thousand USD | -3554.585% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -8975.589% |
| MultiCell Technologies, Inc. | 49.32 USD | 71305858.313% |
| ONE Bio Corp. | 20.12 Million USD | 274.744% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 187.341% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 72018.2% |
| Q BioMed Inc. | -8988.00 USD | -391177.259% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 224.466% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -227908.299% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 179.283% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -2980.664% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 50340.0% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -710077.706% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 25130.605% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -35964.195% |
| GB Sciences, Inc. | -624.00 USD | -5635797.436% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -40779.714% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.465% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -16907592.308% |
| Enzolytics Inc. | 30.7 Thousand USD | 114623.903% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 7389.717% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 103.173% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -6735.241% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 5796.293% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 108.587% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -397009.304% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -41842.063% |
| Kadimastem Ltd | -630.13 Thousand USD | -5481.0% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 3659.583% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 465.914% |
| BioStem Technologies, Inc. | 15.42 Million USD | 327.996% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -297052.514% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 20018.441% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 20018.441% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 2691.326% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -121168.966% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 7914.364% |
| SYBLEU INC | 11.69 Thousand USD | 300783.995% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 863.194% |
| Bioxytran, Inc. | -8285.00 USD | -424377.972% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -9328.418% |
| Neutra Corp. | 14.33 Thousand USD | 245429.613% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -42787.805% |
| PureTech Health plc | -1.6 Million USD | -2093.886% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -3412.459% |
| IXICO plc | 3.27 Million USD | 1175.474% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -4967.435% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -1863.596% |
| CSL Limited | 7.7 Billion USD | 100.456% |
| Cellectis S.A. | 18 Thousand USD | 195477.778% |